alexa Pioglitazone Increases Serum DPP-4 Level in Type 2 Diab
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Pioglitazone Increases Serum DPP-4 Level in Type 2 Diabetes Mellitus

Ippei Kanazawa*, Sayuri Tanaka, Masakazu Notsu and Toshitsugu Sugimoto

Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo 693-8501, Japan

*Corresponding Author:
Ippei Kanazawa, MD, PhD
Department of Internal Medicine 1
Shimane University Faculty of Medicine
Izumo 693-8501, Japan
Tel: +81-853-20-2183
Fax: +81-853-23-8650
E-mail: [email protected]

Received date: July 01, 2014; Accepted date: August 21, 2014; Published date: August 29, 2014

Citation: Kanazawa I, Tanaka S, Notsu M, Sugimoto T (2014) Pioglitazone Increases Serum DPP-4 Level in Type 2 Diabetes Mellitus. J Diabetes Metab 5:416. doi: 10.4172/2155-6156.1000416

Copyright: © 2014 Kanazawa I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Objective: The aim of this study is to clarify the effect of pioglitazone on serum Dipeptidyl peptidase-4 (DPP-4) level in type 2 diabetes mellitus.

Methods: Chronological changes in serum DPP-4 level were observed in 22 patients treated with pioglitazone and 15 with metformin during 12 months. Serum DPP-4 concentrations were measured by an ELISA kit. Results: In the pioglitazone group, serum DPP-4 levels were significantly increased from baseline (774 ± 198 ng/mL) with mean changes of 53 mg/mL [6.8% increase, 95% confidence interval (CI) 2 to 104, p<0.05] after 3 months and of 74 mg/mL (9.4% increase, 95% CI 21 to 126, p<0.01) after 12 months. On the other hand, serum DPP-4 levels were not changed in the metformin group. Percent change in serum DPP-4 level was significantly and positively correlated with percent change in body mass index (r=0.39, p<0.02). The association was still significant even after adjusting for age, duration of diabetes, serum creatinine, and HbAc1 (β=0.59, p<0.02).

Conclusion: The present study showed that pioglitazone, but not metformin, chronologically increased serum DPP-4 levels during 12 months.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords